Lawyers squared off before the New Jersey Supreme Court on Monday for more than four hours in the mass tort alleging that the pharmaceutical giant Hoffmann-La Roche’s anti-acne drug Accutane led to users’ development of Crohn’s disease.

Last year the court agreed to determine whether a trial judge erred in barring plaintiffs’ expert testimony, and whether the plaintiffs can overcome the presumption of adequacy afforded by the Product Liability Act for a drug approved by the federal Food and Drug Administration.